Long-term Use of Mifepristone in the Treatment of Adenomyosis

NCT05151016 · Status: UNKNOWN · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 140

Last updated 2021-12-09

No results posted yet for this study

Summary

The design was a prospective, randomized, positive-control, parallel-group, multicenter clinical trial. The study included a randomized, parallel-group treatment for 24 weeks in 140 subjects from eight hospitals in seven cities across the country who were diagnosed with Adenomyosis and associated symptoms (dysmenorrhea, with or without heavy menstrual flow) , the subjects were randomly assigned to the following two groups:

1. Study Group: mifepristone tablets, 10 mg, 1 tablet daily, taken orally (beginning on the third day of Menstruation) for 24 weeks;
2. Control Group: dafinil (Triptorelin Acetate) , 3.75 mg, first injection on the third day of menstruation, followed by intramuscular injection every 28 days for 24 weeks.

Conditions

Interventions

DRUG

mifepristone

Mifepristone tablets, 10mg, 1 tablet daily, taken orally (beginning on the third day of Menstruation) for 24 weeks

DRUG

Triptorelin Acetate

dafinil, 3.75 mg, first injection on the third day of menstruation, followed by intramuscular injection every 28 days for 24 weeks.

Sponsors & Collaborators

  • Ningbo Women & Children's Hospital

    collaborator OTHER
  • Jiaxing Maternity and Child Health Care Hospital

    collaborator OTHER
  • The Affiliated Hospital of Medical School, Ningbo University

    collaborator UNKNOWN
  • Qilu Hospital of Shandong University

    collaborator OTHER
  • Obstetrics & Gynecology Hospital of Fudan University

    collaborator OTHER
  • The First Affiliated Hospital with Nanjing Medical University

    collaborator OTHER
  • Anhui Provincial Hospital

    collaborator OTHER_GOV
  • Women's Hospital School Of Medicine Zhejiang University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-01
Primary Completion
2023-12-31
Completion
2023-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05151016 on ClinicalTrials.gov